A National Multiple Sclerosis Society grant is supporting an Australian-led research team aiming to better understand how the Epstein-Barr virus (EBV) may be acting as a trigger for multiple sclerosis (MS). The funding will particularly be used to understand what molecules are being targeted by lymphocytes, immune cells that…
lymphocytes
Immune cells from patients with relapsing-remitting multiple sclerosis (RRMS) respond differently to Tecfidera (dimethyl fumarate) based on age, gender, and serum blood glucose levels, a study found. The results suggest these patient-specific factors can modulate the response of immune cells, and should be…
Treating people with relapsing-remitting multiple sclerosis (RRMS) for one year with the immune-modulating therapy Gilenya (fingolimod) reduced the numbers of antibody-producing B-cells and of T helper cells, a study finds. While the…
A genetic variant associated with an increased risk of multiple sclerosis (MS) due to its impact on certain immune system cells can also affect brain cells called astrocytes, a study shows. Reported in the study, “Enhanced astrocyte responses are driven by a genetic risk allele associated with multiple…
Assessing changes in a person’s heart rate can help to predict the degree to which lymphocyte numbers will decrease in relapsing-remitting multiple sclerosis (RRMS) patients using Gilenya (fingolimod), according to a small study. The research, “Fingolimod-induced decrease in heart rate may predict subsequent decreasing degree of…
Shifting from treatment with Gilenya (fingolimod) to Lemtrada (alemtuzumab), and doing a short washout period between the two therapies, does not seem to increase the risk of disease reactivation in patients with multiple sclerosis (MS), an Italian study shows. Lemtrada, marketed by…
News
Small Vesicles Involved in MS Seen to Be Affected by Gilenya, Suggesting Potential as Biomarker
Gilenya (fingolimod) influences the release and function of small membrane particles, called extracellular vesicles, that are involved in the development of multiple sclerosis — and these vesicles may serve a biomarker of treatment effectiveness in people with relapsing MS, researchers report. Extracellular vesicles (EVs) may also work…
Lemtrada (alemtuzumab), a humanized monoclonal antibody, is able to remodel the immune responses of innate immune cells in patients with relapsing-remitting multiple sclerosis (RRMS), according to a recent study. This previously unreported phenotype may contribute to the benefits of the drug for RRMS patients. The study, “Alemtuzumab…
Researchers found that blocking a protein, known as integrin alpha 8, may work to prevent inflammation in the central nervous system of patients with multiple sclerosis (MS). The results were revealed in an oral presentation, “Integrin alpha8 is a novel mediator of T lymphocyte migration across the CNS barriers,” at the 32nd Congress of the European Committee…
Multiple sclerosis patients are at risk of developing lymphopenia, or abnormally low levels of immune defense white blood cells, called lymphocytes, according to a study that investigated lymphocyte counts in people with relapsing MS both before and after the start of treatment. The study, “Lymphopenia in treatment-naive relapsing multiple…
A new study recently published in the journal Annals of Neurology revealed a potential new therapeutic strategy to halt multiple sclerosis (MS) disease progression. The study is entitled “Melanoma cell adhesion molecule–positive CD8 T lymphocytes mediate central nervous system inflammation” and was led by…